Dapagliflozin use in type 1 diabetes: industry, business and ethics

Autor:	Sufyan Hussain, Hilary Nathan, Susannah Rowles
Rok vydání:	2022
Předmět:	General Medicine
Zdroj:	British Journal of Diabetes. 22:47-48
ISSN:	2397-6241 2397-6233
DOI:	10.15277/bjd.2022.344
Popis:	We provide a summary on the unprecedented withdrawal of dapagliflozin’s license in Type 1 diabetes by AstraZeneca. We also provide a summary from a national survey of 52 sites in the United Kingdom, with 70% respondents reporting clinically significant benefits following dapagliflozin use in type 1 diabetes. We describe some of the challenges faced by clinicians supporting people with type 1 diabetes using dapagliflozin. This withdrawal, which was solely for commercial reasons and not due to adverse safety events, raises important considerations about ethics and transparency required from the pharmaceutical industry. It also strongly highlights the need for consultation from key stakeholders including clinicians and patient groups prior to such decisions.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::3fe6230bb5f3e7084206b11dc823b452 https://doi.org/10.15277/bjd.2022.344 Zobrazit plný text záznamu